samedan logo

home > news > detailed info

Wasdell Group strengthens PPFL business with ISO 13485 for medical devices

Wasdell Group

The Wasdell Group, a leading outsourcing partner to companies in the pharmaceutical and biotech sector, has today announced that its Dundalk, Ireland facility has been certified to comply with the ISO 13485 standard for medical device manufacturing.

The ISO 13485 is an internationally recognised certification, ensuring that the company’s quality management system complies to customer and applicable regulatory requirements.

Earlier this year, The Wasdell Group acquired a specialist packaging supplier to the medical device and pharmaceutical sectors, Planned Packaging Films Limited (PPFL).

Planned Packaging brought over 40 years’ experience to The Wasdell Group, supplying leading global medical device manufacturers and pharmaceutical companies in the UK, Europe and the Americas. The ISO standard will further strengthen this offering by providing a base for PPFL services in Ireland.

Graham Wright, Managing Director of PPFL said: “We are delighted that we now have a base in Ireland that can support our continued growth in the medical packaging sector within the UK and Ireland, as well as our export markets.”

Vincent Dunne, CEO at Wasdell, added: “Achieving the ISO 13485 certification allows us to meet the growing needs of customers requiring the medical device standard. It also positions us to support the supply of films and components to existing customers following our acquisition of PPFL that enabled our entry into this space.”

The Wasdell Group already services the European pharmaceutical and biotech sectors from Dundalk with both clinical and commercial packing in a wide variety of packaging formats, including syringes, blisters, containers and sachets. The Wasdell Group offers end-to-end services across pharmaceutical manufacturing, packaging and storage and distribution.
phone +44 (0)1793 777560
email Unit 1-8 Euroway Industrial Estate Blagrove, Swindon Wiltshire, England SN5 8YW
Print this page
Send to a friend
News and Press Releases

Avacta announces license agreement with POINT Biopharma Inc.

Cambridge and Wetherby, UK, 07 January 2021: Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc. (“POINT”), to provide access to Avacta’s pre|CISION technology for the development of tumour-activated radiopharmaceuticals.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement